Leave message
Can’t find what you’re looking for?
Fill out this form to inquire about our custom protein services!
Inquire about our Custom Services >>
Virus-like particles(VLPs) are formed by self-assembly of envelop/capsid proteins from viruses. Membrane Proteins can be constituted in-situ with VLPs produced from HEK293 cell cultures. These VLPs concentrate conformationally intact membrane proteins directly on the cell surface and produce soluble, high-concentration proteins perfect for immunization and antibody screening.
The VLPs provide the display of properly folded membrane proteins in their native cellular membrane in a compact size of 100~300 nm diameter (similar to the size of most viruses) making it optimal targets for dendritic cells in vivo and surface attachment for phage display.
The VLPs are highly immunogenic, so the immunization strategy should be optimized (antigen dose, regimen and adjuvant).
Supplied as 0.2 μm filtered solution in PBS, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
This product is supplied and shipped with dry ice, please inquire the shipping cost.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
Immobilized Human CXCR4 Full Length Protein-VLP (Cat. No. CX4-H5219) at 5 μg/mL (100 μL/well) can bind Human ulocuplumab, Human IgG4 with a linear range of 1-31 ng/mL (QC tested).
The mean peak Radius of VLP is 55-75 nm with more than 95% intensity as determined by dynamic light scattering (DLS).
Price(USD) : $600.00
Price(USD) : $1200.00
Price(USD) : $4180.00
Emerging VoCs, Omicron, Delta, Beta, Alpha mutants and so on, including RBD, S trimer, S1, NTD, NP, etc. These mutants are of high purity and bioactivity and can be used to evaluate the efficacy of the antibodies and vaccination.
ACROBiosystems developed a series of GMP grade cytokines under the GMP grade quality management system. Those products are all suitable for T/NK cell generation, activation, and proliferation in cell therapy research.
50+ targets designed for CAR detection, including PE/FITC/biotin labeled proteins. The key reagents for CD19 and BCMA were FDA DMF filed which can support your IND, NDA and BLA process.
GMP grade cytokines, reagents for cell activation, gene edition, DNA/RNA removal, etc. Particularly focus on product design, quality control and solution-based support to link each phase of your cell and gene therapy journey.
Full length multi-pass TPs with stabilized structure and high bioactivity for immunization, antibody screening, cell based assay and CAR detection, including hot CD20, Claudin 18.2, CD133, GPRC5D,CCR8, CCR5, etc.
CD3 proteins and a collection of for bispecific antibody development which are of high specificity and bioactivities and suitable for immunization, antibody screening.
A series of immune checkpoints including classic co-inhibitory and co-stimulatory receptors. The comprehensive catalog contains 100+ targets with various species and tags, and the high-quality proteins are in good batch-to-batch consistency.
To meet the needs of ADCs development, ACROBiosystems can provide: A variety of high-quality target proteins; MMPs/Cathepsin/uPA for cleavable linker; Anti-payload antibodies & anti-idiotypic antibodies for immunogenicity and PK analysis; SPR/BLI analytical and ADA development service.
Comprehensive collection of Fc receptor proteins, including their common variants, which can help expedite your antibody development.
The MABSOL biotinylated protein collection includes more than a hundred commonly studied drug targets and biomarker proteins.
Comprehensive cytokines including IL families, growth factors, chemokines, TNFs, etc. These products are HEK293 expressed and nearly in authentic structure, high purity and bioactivity, cell based assay/SPR/BLI verified.
To support preclinical/clinical immunogenicity and PK analysis, ACROBiosystems has developed a series of high-affinity anti-idiotypic antibodies. Our pipeline covers five hot targets including adalimum*b, rituxim*b, cetuxim*b, trastuzum*b, and bevacizum*b.
English Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
---|---|---|---|---|---|---|---|---|---|---|
Plerixafor | SDZ-SID-791; JM-3100; JKL-169; AMD-3100; PLR-001; LM-3100 | Approved | Genzyme Corp | Mozobil, Mobozil, 释倍灵 | Mainland China | Lymphoma, Non-Hodgkin; Multiple Myeloma | Genzyme Europe Bv | 2008-12-15 | Colorectal Neoplasms; Rejection of organ transplantation; Sarcoma, Ewing; Brain Neoplasms; Neuroblastoma; Leukopenia; Osteosarcoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Agranulocytosis; Lymphopenia; Pulmonary Fibrosis; Lymphoma, Non-Hodgkin; Leukemia, Myeloid, Acute; Pulmonary Disease, Chronic Obstructive; Granulomatous Disease, Chronic; Lymphoma; Anemia, Sickle Cell; Leukemia, Lymphocytic, Chronic, B-Cell; Adenocarcinoma; Primary Graft Dysfunction; Hematopoietic stem cell transplantation (HSCT); Cystic Fibrosis; Wiskott-Aldrich Syndrome; Bone metastases; Hematologic Neoplasms; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neutropenia; Warts; Agammaglobulinemia; Infections; Hodgkin Disease; Fanconi Anemia; Neoplasms; Myelodysplastic Syndromes; Coronavirus Disease 2019 (COVID-19); Kidney Diseases; Pancreatic Neoplasms; Multiple Myeloma | Details |
English Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
USL-311 | USL-311 | Ligand Pharmaceuticals Inc | Details | ||
PF-06747143 | PF-06747143 | Pfizer Pharmaceuticals Ltd (China) | Details | ||
LEO-35299 | LEO-35299 | Leo Pharma A/S | Details | ||
Balixafortide | POL-6326 | Phase 1 Clinical | Polyphor Ltd | Breast Neoplasms | Details |
LY-2510924 | T-134; LY-2510924 | Eli Lilly And Company | Details | ||
CGT-1881 | CGT1881; CGT-1881 | Phase 1 Clinical | Cgenetech(Suzhou China) Co Ltd | Hematologic Neoplasms; Multiple Myeloma; Lymphoma, Non-Hodgkin | Details |
PTX-9908 | PTX-9908 | Phase 2 Clinical | Pertinax Therapeutics | Carcinoma, Hepatocellular | Details |
X-4136 | X-4136 | Clinical | X4 Pharmaceuticals Inc | Lymphoma, B-Cell | Details |
NRP-2945 | NNZ-4945; NRP-2945 | Phase 2 Clinical | Neuren Pharmaceuticals Ltd | Epilepsy | Details |
68Ga-Pentixather | 68Ga-Pentixather | Phase 1 Clinical | Peking Union Medical College Hospital | Multiple Myeloma | Details |
Ulocuplumab | MDX-1338; BMS-936564 | Phase 2 Clinical | Bristol-Myers Squibb Company | Leukemia; Solid tumours; Multiple Myeloma; Lymphoma, Follicular; Leukemia, B-Cell; Waldenstrom Macroglobulinemia; Leukemia, Myeloid, Acute; Leukemia, Lymphocytic, Chronic, B-Cell | Details |
212-Lead Pentixather | Phase 1 Clinical | National Institutes Of Health, National Cancer Institute, Holden Comprehensive Cancer Center | Small Cell Lung Carcinoma; Lung Neoplasms | Details | |
203-Lead Pentixather | Phase 1 Clinical | National Institutes Of Health, National Cancer Institute, Holden Comprehensive Cancer Center | Small Cell Lung Carcinoma; Lung Neoplasms | Details | |
[68Ga]Pentixafor | Phase 2 Clinical | The University Of Iowa | Neuroendocrine Tumors; Central Nervous System Neoplasms | Details | |
JVS-100 | ACRX-100; GP-51801; GP51801; JVS-100; SRX-100 | Phase 1 Clinical | Cleveland Clinic | Heart Failure; Surgical Wound; Ischemia; Peripheral Arterial Disease | Details |
AD-214 | AD-214 | Phase 1 Clinical | Addpharma Inc, Adalta Ltd | Lung Diseases, Interstitial; Gastroesophageal Reflux | Details |
4-P-021 | 4P021; 4-P-021 | Phase 2 Clinical | 4P-Pharma Ltd, University of Bordeaux, Institut Pasteur De Lille | Coronavirus Disease 2019 (COVID-19) | Details |
GPC-100 | GPC-100 | Phase 2 Clinical | GPCR Therapeutics USA Inc | Multiple Myeloma | Details |
MB-1707 | MB-1707 | Phase 1 Clinical | Mainline Biosciences Inc | Solid tumours; Ovarian Neoplasms; Pancreatic Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
Motixafortide | 4F-Benzoyl-TN14003; TN-14003; TF-14016; BL-8040; BKT-140; GFH-168 | Phase 3 Clinical | Biokine | Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Lymphoid; Esophageal Neoplasms; Pancreatic Neoplasms; Myelodysplastic Syndromes; Myeloproliferative Disorders; Hodgkin Disease; Multiple Myeloma; Anemia, Aplastic; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, T-Cell; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin; Adenocarcinoma; Anemia, Sickle Cell | Details |
Mavorixafor | AMD-11070; X4P-001-IO; AMD-070; X4P-001; X4P-001-RD; X4P-001-LD; ABSK-081 | Phase 3 Clinical | Genzyme Corp | HIV Infections; Carcinoma, Renal Cell; WHIM syndrome; Neutropenia; Triple Negative Breast Neoplasms; Waldenstrom Macroglobulinemia; Melanoma | Details |
This web search service is supported by Google Inc.